Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Xeris Biopharma Holdings Inc. shares valued at $29,000 were purchased by Edick Paul R on Dec 13. At $1.45 per share, Edick Paul R acquired 20,000 shares. The insider’s holdings grew to 1,528,064 shares worth approximately $2.17 million following the completion of this transaction.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Also, Edick Paul R purchased 100,000 shares, netting a total of over 140,380 in proceeds. Following the buying of shares at $1.40 each, the insider now holds 1,508,064 shares.
As published in their initiating research note from Jefferies on October 21, 2022, Xeris Biopharma Holdings Inc. [XERS] has been a Buy and the price target has been revised to $4. This represents a 64.5% premium over Wednesday’s closing price. Analysts at Craig Hallum started covering the stock with ‘”a Buy”‘ outlook in a report released in late April. As of November 17, 2021, SVB Leerink has initiated its “an Outperform” rating for XERS. Earlier on October 29, 2021, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for XERS stock.
Analyzing XERS Stock Performance
On Wednesday, Xeris Biopharma Holdings Inc. [NASDAQ: XERS] rose 2.90% to $1.42. The stock’s lowest price that day was $1.35, but it reached a high of $1.455 in the same session. During the last five days, there has been a surge of approximately 13.60%. Over the course of the year, Xeris Biopharma Holdings Inc. shares have jumped approximately 6.77%. Shares of the company reached a 52-week high of $1.4550 on 03/01/23 and a 52-week low of $0.9701 on 01/05/23. A 50-day SMA is recorded $1.2122, while a 200-day SMA reached $1.5331. Nevertheless, trading volume fell to 1.58 million shares from 0.8 million shares the previous day.
Support And Resistance Levels for Xeris Biopharma Holdings Inc. (XERS)
According to the 24-hour chart, there is a support level at 1.3617, which, if violated, would cause prices to drop to 1.3033. In the upper region, resistance lies at 1.4667. The next price resistance is at 1.5133. RSI (Relative Strength Index) is 64.24 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.1036, which suggests the price will decrease in the coming days. Percent R is at 10.14%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Xeris Biopharma Holdings Inc. subject to short interest?
Stocks of Xeris Biopharma Holdings Inc. saw a sharp rise in short interest on Jan 30, 2023 jumping by 0.65 million shares to 6.49 million. Data from Yahoo Finance shows that the short interest on Dec 29, 2022 was 5.84 million shares. A jump of 10.02% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.56 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.56.
Which companies own the most shares of Xeris Biopharma Holdings Inc. (XERS)?
According to Stonepine Capital Management LLC filings, the company currently owns 11,195,189 shares, which is about 8.23% of the total XERS shares outstanding. The investor’s shares have plunged by -1,732,979 from its previous 13-F filing of 12928168.0 shares. With the completion of the buy transaction, BlackRock Fund Advisors’s stake is now worth $9,410,091. The Vanguard Group, Inc. acquire a 1.41% interest valued at $7.88 million while Caxton Corp. 0 stake. In its current portfolio, Invesco Advisers, Inc. holds 2,000,000 shares valued at $2.48 million.
In terms of Xeris Biopharma Holdings Inc. share price expectations, FactSet research, analysts set an average price target of $5.00 in the next 12 months, up nearly 262.32% from the previous closing price of $1.38. Analysts anticipate Xeris Biopharma Holdings Inc. stock to reach $6.00 by 2023, with the lowest price target being $4.00. In spite of this, 4 analysts ranked Xeris Biopharma Holdings Inc. stock as a Buy at the end of 2023. On April 07, 2021, RBC Capital Mkts assigned a price target of “an Outperform” to the stock and resumed coverage with a $11.